ReviewNeurochemical research2026
Neurochemical Mechanisms Underlying Tanshinone-Mediated Neuroprotection and Formulation Strategies in Cerebral Ischemia/Reperfusion Injury.
Review in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral ischemia/reperfusion (I/R) injury represents a major pathological component of ischemic stroke and is driven by a complex cascade of neurochemical and molecular events, including excitotoxicity, oxidative and nitrosative stress, neuroinflammation, blood-brain barrier (BBB) disruption, mitochondrial dysfunction, and regulated cell death pathways such as apoptosis and ferroptosis. Tanshinones, a class of lipophilic diterpenoid quinones derived from Salvia miltiorrhiza (Danshen), have attracted increasing attention as multi-target neuroprotective agents in experimental models of cerebral I/R. Accumulating evidence demonstrates that major tanshinones, including tanshinone I, tanshinone IIA, tanshinone IIB, cryptotanshinone, and dihydrotanshinone I, modulate key neurochemical processes underlying cerebral I/R injury, including redox homeostasis, inflammatory signaling cascades, mitochondrial function, BBB integrity, and cell death regulatory networks. In parallel, recent advances in formulation strategies, including chemically modified derivatives (e.g., sodium tanshinone IIA sulfonate and the cryptotanshinone derivative DST-3), as well as microemulsions, liposomes, and nanoparticle-based delivery systems, have markedly improved aqueous solubility, pharmacokinetic behavior, and brain bioavailability of tanshinones, thereby potentially enhancing their neuroprotective effects in experimental models. This review comprehensively summarizes current evidence on the neurochemical and molecular mechanisms of tanshinones and their formulations in cerebral I/R injury, with an emphasis on signaling pathway modulation, redox regulation, mitochondrial protection, and formulation-driven improvements in brain delivery, and discusses remaining mechanistic challenges and future research directions.
Indexed as
Identifiers
42260052What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.